Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to Intellia Therapeutics' fourth quarter and full year 2025 conference call. My name is Drew and I will be your conference operator today. Please be advised that today's call is being recorded. I will now turn the call over to Jason Fredette, Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed. Thank you, operator, and hello, everyone. Earlier this morning, we issued a press release outlining recent business updates and our fourth quarter and full year financial results. This document can be found on the investors and media section of Intellia's website at intelliatx.com. At this time, I would like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements. We ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intelia undertakes no duty to update this information unless required by law. Joining me on this call are John Leonard, our Chief Executive Officer, and Ed Dulac, our Chief Financial Officer. With that, I'll turn the call now over to John to begin our business discussion. Thank you, Jason, and thanks to all of you who have tuned in for today's call. We'll begin with a brief recap of our 2025 accomplishments, and we'll then review the status of our NEXE program in ATTR amyloidosis. After that, we'll provide updates on the significant progress we've made with LOMVOSI, which is being developed as a potential one-time treatment for patients with hereditary angioedema, or HAE. And we will close with Ed's financial review. First, let's take a step back to the origins of Intellia Therapeutics. This company was formed ...